Over the past week, the Hang Seng Index rose 1.17% to close at 26205.91. This week's IPO market is relatively cold, a total of two new shares delivery table, three new shares have been heard, no new offerings and one new share listing.

Notably, Novi Health of CRO, the largest biotechnology contract research organization in the Asia-Pacific region, and BM Medical, a medical device company specializing in the development of interventional respiratory products, were heard this week.

The new stock listed this week is "the first share of the pub"$Helens (09869.HK) $The performance was bright, closing up 22.91% on the first day, with a market capitalization of HK $30.295 billion. In the previous public offering stage, Helens publicly placed 28000 applicants, with a success rate of 60%, and 3 subscriptions were firmly in one hand.

There are a total of 2 IPOs in the past week:

Yunkang GroupIs a comprehensive medical operation service provider in China, providing a full range of diagnostic testing services for medical institutions, followed by services for non-medical institutions. In terms of revenue, the company will be the fifth largest company in China's medical operation and service market in 2020, with a market share of 3.7%.

Happy to meetIs a supplier of automotive financial leasing services, has been successfully transformed into an automotive service supplier, providing a variety of solutions related to automotive retail, automotive financing and auto-related services. The Group's main business includes: automobile retail and financing and automobile-related services. According to the cautionary report, in terms of transaction volume, the company ranked eighth among China's third-party automobile retail financial leasing companies in terms of transaction volume in the year ended December 31, 2020, with a market share of 1%.

Norway HealthIs a contract research organization specializing in the field of biotechnology. Based on the Asia-Pacific market, the company mainly provides services to biotechnology companies and small and medium-sized pharmaceutical companies headquartered in Asia, North America and Europe.

According to Frost Sullivan, in terms of revenue, the company accounted for 4.1% of the Asia-Pacific clinical contract research organization market for biotechnology companies and small and medium-sized pharmaceutical companies in 2020, which accounted for 51.8% of the Asia-Pacific clinical contract research organization market in the same year.

In terms of performance, the company is developing well. Revenue in 2020 reached US $166 million, with a compound annual growth rate of 32.2%In terms of net profit, the net profit reached US $4.106 million, which means that the company is already profitable as a type of service organization.

As the head player of CRO in the Asia-Pacific region, Norway Health alsoFavored by some star investment institutions, TPG, as its controlling shareholder, controls about 74.60% of its shares.Sequoia Capital, GIC, Caesar Foundation Hospital and other well-known investment banks are also among the company's shareholders.

Bo medical treatmentA medical device company specializing in the development of interventional respiratory products, founded in 2012, is a pioneer in the field of interventional respiratory medicine, providing innovative lung disease solutions in China and around the world. Using proprietary whole lung arrival navigation technology, the company has developed a comprehensive interventional respiratory platform including navigation, diagnosis and treatment. the pain points of the existing diagnosis and treatment models and the huge unmet medical needs of lung diseases have been solved by improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease.

The company's core products are InterVapor and RF-II. According to Frost Sullivan dataInterVapor is the first and only thermal steam ablation system in the world for the treatment of lung diseases such as chronic obstructive pulmonary disease and lung cancer.。

The company is the market leader of domestic interventional respiratory navigation equipment. For the years ending 2018, 2019 and 2020In terms of sales volume, the company ranks first in the market for respiratory navigation equipment in China.It occupies 43.2% market share and ranks second in terms of sales revenue, accounting for 37.5% market share.

There has been only one new stock in the past week.$Helens (09869.HK) $The motherboard is listed.

Helens is China's largest pub chain network, ranking first in China's pub industry by revenue in 2020, accounting for 1.1% of the market. According to Frost Sullivan, the company remained a market leader in the Chinese tavern industry in 2018, 2019 and 2020 and for the three months ending March 31, 2021 in terms of the number of taverns.

The company has been operating taverns under the "Helen's" brand, and with the help of a highly standardized operation model, the size of its tavern network has expanded rapidly during the track record period.

On the marketHelens opened 16.59% higher on the first day, and then continued to rise, rising nearly 30% in intraday trading before closing up 22.91% at HK $24.3, with a market capitalization of more than HK $30 billion.

In the previous public offering stage, Helens publicly placed 28000 applicants, with a success rate of 60% in one hand and 60% in the first hand, with a steady success rate in 3 subscription hands.